The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Preliminary Evidence of Riluzole Efficacy in Antidepressant-Treated Patients with Residual Depressive Symptoms
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“…now more than 20 different antidepressant medications available in the US, treatment-resistant depression remains a common problem, with up to half of depressed patients failing to respond sufficiently to adequate trials of antidepressant medications (Fava and Davidson 1996; Trivedi et al 2006).”
BackgroundThe possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death
Sapolsky, R. M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00971-9 · Cited by 699 · cited 1×
“…increases in extracellular glutamate (Moghaddam 1993), alterations in hippocampal glutamate receptor subunit gene expression (Bartanusz et al 1995) and excitotoxic-like effects of excessive glutamate transmission (Sapolsky 2000) serve as potential mediators between stress and mood disorders.”
BackgroundMoghaddam, B. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13387.x · Cited by 567
Katoh, R., Asano, T., Ueda, H., Morishita, R., Takeuchi, I. K., Inaguma, Y., & Kato, K. (2002) · The FASEB Journal · doi:10.1096/fj.02-0143fje · Cited by 193
Mizuta, I., Ohta, M., Ohta, K., Nishimura, M., Mizuta, E., & Kuno, S. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02098-5 · Cited by 145 · cited 1×
“…may contribute to its antidepressant properties, including increasing brain derived neurotrophic factor (BDNF) expression and promoting hippocampal cell proliferation (KatohSemba et al 2002; Mizuta et al 2001) through pathways that may or may not involve its effects on the glutamatergic system.”
Background
Cited by
Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
Self-citationMahmoud, S., Gharagozloo, M., Simard, C., & Gris, D. (2019) · Cells · doi:10.3390/cells8020184 · Cited by 698
Increased Levels of Glutamate in Brains from Patients with Mood Disorders
Hashimoto, K., Sawa, A., & Iyo, M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.017 · Cited by 609
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605
The GABA system in anxiety and depression and its therapeutic potential
Möhler, H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.040 · Cited by 590
Magnetic Resonance Spectroscopy Studies of Glutamate-Related Abnormalities in Mood Disorders
Yüksel, C., & Öngür, D. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.016 · Cited by 493
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Stuck in a rut: rethinking depression and its treatment
Holtzheimer, P. E., & Mayberg, H. S. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2010.10.004 · Cited by 430
Pittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
Ketamine for Depression: Where Do We Go from Here?
aan het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.003 · Cited by 418
Maternal separation as a model of brain-gut axis dysfunction
O’Mahony, S. M., Hyland, N. P., Dinan, T. G., & Cryan, J. F. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2010-9 · Cited by 415
Glutamate-based antidepressants: 20 years on
Skolnick, P., Popik, P., & Trullas, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.002 · Cited by 380
Bernard, R., Kerman, I. A., Thompson, R. C., Jones, E. G., Bunney, W. E., Barchas, J. D., Schatzberg, A. F., Myers, R. M., Akil, H., & Watson, S. J. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.44 · Cited by 372
Ibrahim, L., DiazGranados, N., Franco-Chaves, J., Brutsche, N., Henter, I. D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D. A., Manji, H. K., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.338 · Cited by 309
Kanner, A. M., Schachter, S. C., Barry, J. J., Hersdorffer, D. C., Mula, M., Trimble, M., Hermann, B., Ettinger, A. E., Dunn, D., Caplan, R., et al. (2012) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2012.01.007 · Cited by 295
Mathew, S. J., Murrough, J. W., aan het Rot, M., Collins, K. A., Reich, D. L., & Charney, D. S. (2010) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000169 · Cited by 294
Inflammation, Glutamate, and Glia in Depression:A Literature Review
McNally, L., Bhagwagar, Z., & Hannestad, J. (2008) · CNS Spectrums · doi:10.1017/s1092852900016734 · Cited by 289
Sex differences in glutamate receptor gene expression in major depression and suicide
Gray, A. L., Hyde, T. M., Deep-Soboslay, A., Kleinman, J. E., & Sodhi, M. S. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.91 · Cited by 250
Glutamatergic Modulators: The Future of Treating Mood Disorders?
Zarate, C., Machado-Vieira, R., Henter, I., Ibrahim, L., Diazgranados, N., & Salvadore, G. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673229.2010.511059 · Cited by 228
Glial and glutamatergic markers in depression, alcoholism, and their comorbidity
Miguel-Hidalgo, J. J., Waltzer, R., Whittom, A. A., Austin, M. C., Rajkowska, G., & Stockmeier, C. A. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.06.003 · Cited by 218
“For instance, magnetic-resonance-spectroscopy (MRS) studies in MDD have reported low levels of glutamate and glutamate/glutamine in the PFC (Hasler et al., 2007) or a negative correlation of duration of depression with glutamate levels J Affect Disord.”
BackgroundResultInfluentialMiller, O. H., Moran, J. T., & Hall, B. J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.028 · Cited by 200
Riluzole in the Treatment of Mood and Anxiety Disorders
Pittenger, C., Coric, V., Banasr, M., Bloch, M., Krystal, J. H., & Sanacora, G. (2008) · CNS Drugs · doi:10.2165/00023210-200822090-00004 · Cited by 177
Self-citationMachado-Vieira, R., Manji, H. K., & Zarate, C. A. (2009) · The Neuroscientist · doi:10.1177/1073858409336093 · Cited by 171
Brennan, B. P., Hudson, J. I., Jensen, J. E., McCarthy, J., Roberts, J. L., Prescot, A. P., Cohen, B. M., Pope, H. G., Renshaw, P. F., & Öngür, D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.191 · Cited by 168
Dysfunctional hippocampal activity affects emotion and cognition in mood disorders
Femenía, T., Gómez-Galán, M., Lindskog, M., & Magara, S. (2012) · Brain Research · doi:10.1016/j.brainres.2012.03.053 · Cited by 143
Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression
Lener, M. S., Kadriu, B., & Zarate, C. A. (2017) · Drugs · doi:10.1007/s40265-017-0702-8 · Cited by 131
“Consistent with a case report of antidepressant response to riluzole as an augmentation strategy in patients concurrently treated with traditional antidepressants [107], a second open-label study of ten patients with MDD showed a reduction in both depressive and anxiety symptoms after the first week and throughout the…”
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Mechanisms of antidepressant resistance
El-Hage, W., Leman, S., Camus, V., & Belzung, C. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00146 · Cited by 111
Novel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92
Striatal structure and function in mood disorders: a comprehensive review
Marchand, W. R., & Yurgelun‐Todd, D. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00874.x · Cited by 91
An update on the role of glutamate in the pathophysiology of depression
Mitchell, N. D., & Baker, G. B. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01529.x · Cited by 91
Coplan, J. D., Gopinath, S., Abdallah, C. G., & Berry, B. R. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00189 · Cited by 90
Grant, P., Song, J. Y., & Swedo, S. E. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0009 · Cited by 84
Pittenger, C., Bloch, M. H., Wasylink, S., Billingslea, E., Simpson, R., Jakubovski, E., Kelmendi, B., Sanacora, G., & Coric, V. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09123 · Cited by 80
New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity
Huang, Y.-J., Lane, H.-Y., & Lin, C.-H. (2017) · Neural Plasticity · doi:10.1155/2017/4605971 · Cited by 74
Intravenous Ketamine “Burst” for Refractory Depression in a Patient with Advanced Cancer
Stefanczyk-Sapieha, L., Oneschuk, D., & Demas, M. (2008) · Journal of Palliative Medicine · doi:10.1089/jpm.2008.9828 · Cited by 61
Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
de Sousa, R. T., V. Zanetti, M., R. Brunoni, A., & Machado-Vieira, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630173522 · Cited by 43
“In open-label clinical trials, riluzole, another glutamatergic agent, have significantly decreased depressive symptoms after 1-2 weeks of treatment in TRD patients [96, 97].”
BackgroundPediatric psychopharmacology: Too much or too little?
Rapoport, J. L. (2013) · World Psychiatry · doi:10.1002/wps.20028 · Cited by 44
Chen, J.-X., Yao, L.-H., Xu, B.-B., Qian, K., Wang, H.-L., Liu, Z.-C., Wang, X.-P., & Wang, G.-H. (2014) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-014-1362-5 · Cited by 39
Sugiyama, A., Saitoh, A., Iwai, T., Takahashi, K., Yamada, M., Sasaki-Hamada, S., Oka, J.-I., Inagaki, M., & Yamada, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.02.012 · Cited by 38
Longer-term open-label study of adjunctive riluzole in treatment-resistant depression
Sakurai, H., Dording, C., Yeung, A., Foster, S., Jain, F., Chang, T., Trinh, N.-H., Bernard, R., Boyden, S., Iqbal, S. Z., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.06.065 · Cited by 20
“Although riluzole has shown promise as monotherapy or augmentation therapy in treatmentresistant mood disorders in open-label human studies (Zarate et al., 2004; Zarate et al., 2005; Sanacora et al., 2007; Brennan et al., 2010), it was not more effective than placebo for the treatment of bipolar depression in the two…”
BackgroundAnnouncing the first novel class of rapid-onset antidepressants in clinical practice
Fasipe, O., Akhideno, P., Owhin, O., & Ibiyemi-Fasipe, O. (2019) · Journal of Medical Sciences · doi:10.4103/jmedsci.jmedsci_36_19 · Cited by 6
Metadata
- Authors
- Sanacora, G., Kendell, S. F., Levin, Y., Simen, A. A., Fenton, L. R., Coric, V., & Krystal, J. H.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2007-03
- Volume
- 61
- Issue
- 6
- Pages
- 822-825
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2039961483
- Cited by
- 199
- References
- 5
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.